Crikker, My take is that if BP owned AMRN, Vascepa sales would be far
higher than AMRN in a GIA approach. In Europe, direct to consumer
advertising is not allowed, so AMRN will either have to partner with
a BP or sell the company to a BP, if they find an acceptable offer.
With Epanova not a threat and with generics not allowed in Europe
for around 11 years, Europe, in my opinion, could be far more valuable
(at least in a buyout) than what most analysts expect, and perhaps even
more valuable than the US. I don't know what JT or his BOD intend to
do, however, I think if the right takeout offer is made, JT and the BOD
would have no problem agreeing to it. (If they have a secret agenda I
would think it is more likely to plan for a sale of the company rather
than a plan to GIA.)
News 
Market Data 
Discover 
